– Concerto HealthAI, a provider of real-world evidence (RWE) services for precision oncology raises $150M in Series B funding led by Declaration Partners.
– Series B funding will power next-generation clinical research, accelerate breakthrough therapies, and improve patient outcomes.
Concerto HealthAI, a Boston, MA-based provider of Real-World Data (RWD) and enterprise AI technology solutions for Precision Oncology raised $150 million in aggregate Series B financing. The round of financing was led by Declaration Partners with participation from Maverick Ventures, AllianceBernstein PCI, and SymphonyAI Group. The Series B funding will support Concerto HealthAI’s continued innovation in RWD and technology products and services for regulatory and non-regulatory applications, expansion into adjacent therapy areas, and commercial patient solutions.
Delivering High-Performance RWE
Founded in 2017, Concerto HealthAI is revolutionizing the combination of data and AI to get the right medicines to the right patients faster. Concerto HealthAI has assembled the broadest and most representative clinical network in the industry, through partnerships with the foremost community oncology networks and exclusive licensing with CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology (ASCO). These partnerships and relationships are across all major Electronic Medical Record environments, inclusive of next generation sequencing diagnostic information and Patient Reported Outcomes. Concerto HealthAI engineers use case-aligned, AI-enriched, validated, and production-ready RWD products and complementary AI-enabled cloud technologies for precision research and patient solutions.
With 90 percent year-over-year revenue growth, Concerto HealthAI has an expanding list of partners and customers: three of the world’s major biopharmaceutical and oncology organizations have deployed eurekaHealth, and 19 out of the top 25 biopharma are customers of Concerto HealthAI technologies and services.
“The significant commitment and life sciences expertise of our investors validates and accelerates our strategy,” said Jeff Elton, PhD, CEO of Concerto HealthAI. “This investment underscores the amazing team and talent we have brought together with a common purpose of advancing Precision Oncology solutions for the most devastating cancers based on our engineered RWD, AI-enabled technologies, and advanced scientific services.”
Concerto HealthAI Launches eurekaHealth 3.0: Enterprise RWE & AI Solutions Environment
In addition to the Series B funding announcement, the company also announced the release of eurekaHealth 3.0, the first combination of use-case aligned RWD and AI technologies to deliver high-performance real-world evidence (RWE) insights and services with unprecedented speed, precision, and confidence for oncology clinical development in the life sciences industry.
With eurekaHealth 3.0, Concerto HealthAI combines the largest and most comprehensive array of research-ready RWD with advanced AI capabilities for “on-demand” precision analyses and patient insights. Researchers across the enterprise can now readily access data, including clinical and genomic data, engineered for and aligned to specific use-cases– through intuitive drag and drop and natural language search – to ask meaningful questions and gather insights quickly.
Concerto HealthAI is deploying this new version of eurekaHealth in multi-disease collaborations with some of the world’s largest biopharmaceutical companies including Janssen, Pfizer, and Bristol-Meyers Squibb to optimize drug development and advance patient therapies and outcomes.